Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Viral vectors and plasmid DNA are products of gene therapy, which are used for the treatment of a large number of diseases. The advantages of gene vaccines and gene therapy over conventional vaccines and therapies include the ability to induce a wider range of immune response types. The global viral vector and plasmid DNA manufacturing market is expected to register a CAGR of 19.5% during the forecast period (2018 - 2023).
Increase in the Number of Clinical Studies
There are a number of clinical studies being conducted on viral vectors and plasmid DNA manufacturing that have emphasized the potential of gene therapy, to address important medical needs, and initiated a surge of investments in drug development and commercialization of these therapies. Genetic markers are associated with many complex diseases, and it is the need of the hour to explore, how genetic information, in conjunction with clinical information, can be used in the design of prevention trials, so that the results can be used in gene therapy product manufacturing. This increase in the number of clinical studies is driving the market.
Technological advancements to mitigate challenges posed by conventional methods of vector production and growing number of gene therapy candidates, coupled with their rapid progression through the various phases of clinical developments, are some of the other factors contributing to the growth of the market.
High Cost of Gene Therapies
The extent of the potential of gene therapy to combat genetic disorders that are beyond conventional cure is unparalleled. The support afforded by patient organizations to gene therapy is significant, and the field is indebted to the thousands of patient volunteers, who have taken part in clinical trials over decades. But, the actual problem is whether gene therapies are accessible and affordable to the patients or not. To date, companies have sought extraordinarily high prices for gene therapy products that reach the market. The readiness and ability of healthcare systems to afford these products will determine whether or not the potential of gene therapies will be fully realized. It is essential to question whether the prices sought by companies are truly justified. The high cost of the gene therapies is hampering the growth of the market.
Additionally, increase in regulatory scrutiny and challenges in viral vector-manufacturing capacity, are also restraining the growth for viral vector and plasmid DNA manufacturing market, across the world.
Asia-Pacific to be a Lucrative Market
The global viral vector and plasmid DNA manufacturing market is segmented by product type, application, and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
Asia-Pacific possesses high market potential, owing to the increase in awareness about vector products, and rise in the viral and non-viral vector applications. This region is anticipated to experience fast-paced growth, in terms of development and use of viral vector and plasmid DNA.
Major players: FUJIFILM DIOSYNTH BIOTECHNOLOGIES, SANOFI, SPARK THERAPEUTICS, UNIQURE, MASSBIOLOGICS, FINVECTOR, BRAMMER BIO, CELL AND GENE THERAPY CATAPULT, AND COBRA BIOLOGICS, amongst others.
Reasons to Purchase The Report
• Market analysis for the global viral vector and plasmid DNA manufacturing market, with region-specific assessments and competition analysis on a global and regional scale
• Analyze various perspectives of the industry, with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness the fastest growth during, the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 month analyst support, along with the market estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Increase in the Number of Clinical Studies
There are a number of clinical studies being conducted on viral vectors and plasmid DNA manufacturing that have emphasized the potential of gene therapy, to address important medical needs, and initiated a surge of investments in drug development and commercialization of these therapies. Genetic markers are associated with many complex diseases, and it is the need of the hour to explore, how genetic information, in conjunction with clinical information, can be used in the design of prevention trials, so that the results can be used in gene therapy product manufacturing. This increase in the number of clinical studies is driving the market.
Technological advancements to mitigate challenges posed by conventional methods of vector production and growing number of gene therapy candidates, coupled with their rapid progression through the various phases of clinical developments, are some of the other factors contributing to the growth of the market.
High Cost of Gene Therapies
The extent of the potential of gene therapy to combat genetic disorders that are beyond conventional cure is unparalleled. The support afforded by patient organizations to gene therapy is significant, and the field is indebted to the thousands of patient volunteers, who have taken part in clinical trials over decades. But, the actual problem is whether gene therapies are accessible and affordable to the patients or not. To date, companies have sought extraordinarily high prices for gene therapy products that reach the market. The readiness and ability of healthcare systems to afford these products will determine whether or not the potential of gene therapies will be fully realized. It is essential to question whether the prices sought by companies are truly justified. The high cost of the gene therapies is hampering the growth of the market.
Additionally, increase in regulatory scrutiny and challenges in viral vector-manufacturing capacity, are also restraining the growth for viral vector and plasmid DNA manufacturing market, across the world.
Asia-Pacific to be a Lucrative Market
The global viral vector and plasmid DNA manufacturing market is segmented by product type, application, and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.
Asia-Pacific possesses high market potential, owing to the increase in awareness about vector products, and rise in the viral and non-viral vector applications. This region is anticipated to experience fast-paced growth, in terms of development and use of viral vector and plasmid DNA.
Major players: FUJIFILM DIOSYNTH BIOTECHNOLOGIES, SANOFI, SPARK THERAPEUTICS, UNIQURE, MASSBIOLOGICS, FINVECTOR, BRAMMER BIO, CELL AND GENE THERAPY CATAPULT, AND COBRA BIOLOGICS, amongst others.
Reasons to Purchase The Report
• Market analysis for the global viral vector and plasmid DNA manufacturing market, with region-specific assessments and competition analysis on a global and regional scale
• Analyze various perspectives of the industry, with the help of Porter’s five forces analysis
• The treatment type that is expected to dominate the market
• Regions that are expected to witness the fastest growth during, the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 month analyst support, along with the market estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
